Is Retatrutide Approved Yet?

Is Retatrutide FDA Approved?

No. Retatrutide (LY3437943) is not FDA approved, EMA approved, or cleared by any other regulatory body as of March 9, 2026. Eli Lilly has not submitted a New Drug Application to the FDA. The compound remains in Phase 3 clinical trials under the TRIUMPH program, and no prescription medicine containing retatrutide is available at any pharmacy.

The first Phase 3 data readout came from TRIUMPH-4 on December 11, 2025, which studied retatrutide in adults with obesity and moderate-to-severe knee osteoarthritis. While the results were positive, a full regulatory submission requires data from multiple trials across the TRIUMPH program.

Why Hasn’t the FDA Approved Retatrutide Yet?

FDA approval of any weight loss drug requires completion of Phase 3 clinical trials demonstrating efficacy, safety in a broad patient population, and an acceptable benefit-risk profile. Retatrutide’s development is still in the data-accumulation stage: only one of eight TRIUMPH trials has reported results so far. The remaining seven trials will provide the body of evidence the FDA needs to evaluate this drug for treatment of obesity and related conditions. Until that data package is complete and reviewed, retatrutide cannot be prescribed by clinicians or dispensed by pharmacies.

What Are the TRIUMPH Phase 3 Results So Far?

As of March 9, 2026, only one TRIUMPH Phase 3 trial has reported results: TRIUMPH-4, announced December 11, 2025. This trial studied retatrutide in adults with obesity and moderate-to-severe knee osteoarthritis over 68 weeks.

TRIUMPH-4 Efficacy Data

The headline: 28.7% mean body weight loss at the 12 mg dose — the highest weight-loss figure ever reported in a Phase 3 obesity trial. Participants on 12 mg lost an average of 71.2 lbs (32.3 kg). The placebo group achieved approximately 2–3% body weight reduction, underscoring the drug’s efficacy. Participants in clinical trials for retatrutide may not be guaranteed to receive the active drug, as many trials are randomized and blinded against a placebo group.

Beyond weight, TRIUMPH-4 was the first obesity drug trial to demonstrate significant improvement in osteoarthritis pain, with WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain scores reduced by 4.5 points (75.8% improvement). This positions retatrutide not just as a weight loss drug but as a potential treatment for obesity-related health conditions that affect patients’ physical activity and well-being.

Remaining TRIUMPH Readouts

Seven additional TRIUMPH trials (TRIUMPH-1 through TRIUMPH-3, TRIUMPH-5 through TRIUMPH-8) are expected to read out throughout 2026, covering obesity, type 2 diabetes, MASH/NASH (metabolic dysfunction-associated steatohepatitis), obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease. The MASH indication is significant: retatrutide is intended to treat not only obesity and type 2 diabetes but also metabolic dysfunction-associated steatohepatitis, which has limited treatment options. These clinical trials will provide the safety and efficacy data needed for a comprehensive regulatory submission.

What About the Dysesthesia Safety Signal?

In TRIUMPH-4, approximately 20.9% of patients on the highest retatrutide dose reported dysesthesia — a skin sensitivity phenomenon described as tingling, tenderness, or altered sensation. This was higher than the rate seen in Phase 2 and is the most notable non-GI safety signal to emerge from the program so far.

Dysesthesia is not life-threatening and was generally described as mild to moderate in severity. However, the rate is clinically meaningful and distinguishes retatrutide from other GLP-1-class drugs, which do not typically produce this side effect. Eli Lilly has stated that the signal is being monitored across all ongoing TRIUMPH trials.

Whether dysesthesia affects regulatory review or labeling remains to be seen. The FDA will weigh this signal against the overall benefit-risk profile when the NDA is eventually submitted.

Adverse Events in Retatrutide Trials

Across Phase 2 and Phase 3 clinical trials, the most frequently reported adverse events with retatrutide have been gastrointestinal in nature. Nausea, diarrhea, vomiting, and constipation were the leading symptoms, consistent with the known side-effect profile of GLP-1 drugs and other incretin-based medications. These adverse events generally peaked during the dose-titration period and diminished as patients continued treatment at higher doses.

At the 12 mg dose in TRIUMPH-4, nausea and vomiting rates were comparable to those seen with other weight loss drugs such as semaglutide and tirzepatide. Decreased appetite — a pharmacological effect of the GLP-1 and GIP hormones that retatrutide activates — was commonly reported but is generally considered a therapeutic mechanism rather than an adverse event. Discontinuation rates due to adverse events remained low, suggesting the drug’s risks are manageable for most patients treated in clinical trials.

A healthy diet and physical activity were recommended alongside retatrutide in all TRIUMPH protocols, which is standard practice for obesity medicine clinical trials. Before enrolling in a clinical trial for retatrutide, individuals go through an informed consent process to understand the risks and benefits. Full side-effect data by dose is available in our retatrutide side effects guide.

When Will Retatrutide Be Approved?

No approval date has been confirmed. Based on publicly available information, the most likely timeline is:

2026: Phase 3 data accumulation. Seven remaining TRIUMPH trials are expected to read out throughout 2026. These cover the full range of target indications — obesity, type 2 diabetes, MASH, sleep apnea, heart failure, osteoarthritis, and CKD. Eli Lilly needs a critical mass of Phase 3 data before filing.

Late 2026 or early 2027: NDA filing. Assuming the remaining TRIUMPH readouts are positive and the dysesthesia signal is manageable, Eli Lilly is expected to file a New Drug Application with the FDA in the second half of 2026 or the first quarter of 2027.

Q1–Q2 2027: Potential FDA approval. Under standard FDA review (10-month timeline), an approval decision could come as early as Q1 2027 if filing happens in mid-2026, or Q2 2027 for a late-2026 submission. Priority Review designation, if granted, would shorten this to 6 months. Track all upcoming decisions on the obesity drug approval tracker.

Can You Get a Retatrutide Prescription?

No. Because retatrutide is not an approved drug, it cannot be prescribed by a doctor or dispensed by any pharmacy. There is no prescription pathway, no off-label prescribing option, and no legitimate online pharmacy that carries this medicine. Retatrutide is only legally available through participation in Eli Lilly’s clinical trials. For a full breakdown of current availability and sourcing considerations, see our guide to buying retatrutide.

Concerns About Illegal Sales

The FDA has issued warnings against the illegal sale of retatrutide and other GLP-1 drugs online. Any claims of retatrutide being sold online outside of clinical trials are not legitimate and are illegal. Patients who buy unapproved medications from unregulated sources face serious health concerns: products may be contaminated, mislabeled, or contain no active ingredient at all. Unlike approved alternatives such as semaglutide or tirzepatide, retatrutide has no verified pharmaceutical supply chain and no regulatory oversight outside of Eli Lilly’s controlled trial environment.

How to Find Retatrutide Clinical Trials

To find clinical trials for retatrutide, individuals can search on ClinicalTrials.gov using the search term “retatrutide” or “LY3437943.” Clinical trials for retatrutide are expected to complete in 2026, and enrollment may still be open at participating sites. Discuss eligibility with your healthcare provider to determine whether a retatrutide trial is an appropriate option for your health goals, including whether the drug may help you lose weight as part of a supervised research protocol.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational once-weekly injectable drug developed by Eli Lilly that simultaneously activates three gut hormones: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. It is the first drug targeting all three of these hormones to reach Phase 3 clinical trials for the treatment of obesity. For a detailed breakdown of each receptor’s contribution, see our triple-agonist pathway analysis.

How Retatrutide Differs from Other Weight Loss Medications

The three-hormone mechanism is the key differentiator. Currently approved medications for weight management include semaglutide (Wegovy) and tirzepatide (Zepbound), which target one or two of these hormones. Retatrutide adds glucagon receptor activation on top of the GLP-1 and GIP pathways used by tirzepatide. For a head-to-head comparison with these alternatives, see Retatrutide vs Tirzepatide vs CagriSema. Glucagon receptor signaling increases energy expenditure, promotes hepatic fat oxidation, and enhances lipid metabolism — pathways that may explain why patients on retatrutide lose more weight than those on existing drugs. Several other pharmaceutical companies are also developing multi-receptor obesity medicines, but retatrutide is the furthest along in clinical development.

In the Phase 2 trial published in the New England Journal of Medicine in 2023, the 12 mg dose produced 24.2% mean body weight loss at 48 weeks — at the time, the highest weight loss ever reported for any anti-obesity drug. The Phase 3 TRIUMPH-4 result (28.7% at 68 weeks) extended that lead further, establishing retatrutide as the most effective investigational medicine for treating obesity in terms of weight reduction. For detailed dosing protocols and click-to-dose tables, see our retatrutide dosage guide. Retatrutide is available for research in 30mg and 20mg prefilled pen formats, including research availability in Dubai. For a ranked comparison of verified research suppliers, see our best research peptides 2026 guide.